Tianjin Ringpu Bio-Technology (300119) Fundamentals 2026 — P/E 18.4x, Revenue Analysis | SniperIQ
Tianjin Ringpu Bio-Technology (300119) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.4B, trading at ¥15.92 on the SHZ. This SniperIQ fundamentals page covers Tianjin Ringpu Bio-Technology's valuation (P/E 18.4x, P/B 1.5x), profitability (net margin 11.5%), revenue (¥3.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tianjin Ringpu Bio-Technology's market cap?
Tianjin Ringpu Bio-Technology (300119) has a market capitalization of approximately ¥7.4B, trading at ¥15.92 on the SHZ. Market cap moves with the live share price.
What is Tianjin Ringpu Bio-Technology's P/E ratio?
Tianjin Ringpu Bio-Technology's trailing twelve-month P/E ratio is 18.4x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tianjin Ringpu Bio-Technology?
Tianjin Ringpu Bio-Technology runs a net profit margin of 11.5%, a gross margin of 40.9%, and an operating margin of 13.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tianjin Ringpu Bio-Technology generate?
Tianjin Ringpu Bio-Technology reported revenue of ¥3.4B for fiscal year 2025, with net income of ¥401M and earnings per share (EPS) of 0.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tianjin Ringpu Bio-Technology pay a dividend?
Tianjin Ringpu Bio-Technology offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tianjin Ringpu Bio-Technology financially healthy?
Tianjin Ringpu Bio-Technology carries a debt-to-equity ratio of 0.35x and a current ratio of 1.81x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tianjin Ringpu Bio-Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tianjin Ringpu Bio-Technology (300119) the key facts are: market cap ¥7.4B, P/E 18.4x, revenue ¥3.4B, 52-week range 13.91-24.03. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tianjin Ringpu Bio-Technology's full fundamentals live
Get Tianjin Ringpu Bio-Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.